PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
AstraZeneca to invest $360m in advanced manufacturing facility in Ireland

Investment will transform development and commercialisation of new medicines

AstraZeneca is planning on establishing a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland to ensure the Company’s global supply network is fit for future growth.

The new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility. 

The $360m planned investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 highly skilled direct jobs, including scientists and engineers, and further indirect jobs. The project, which will provide an important boost to the local economy and to the country’s life-sciences sector, was developed with the support and collaboration of Ireland’s investment agency, IDA Ireland.

Micheál Martin, Taoiseach, said: “I warmly welcome today’s announcement from AstraZeneca that it is to establish its first ever manufacturing facility in Ireland. This $360 million investment represents a significant commitment to Ireland and will see 100 jobs being created. In choosing Ireland as the location for its new next-generation active pharmaceutical ingredient manufacturing facility, AstraZeneca joins the very strong and successful network of global life sciences companies we have in Ireland. I wish them every success with their operations here.”

Pascal Soriot, Chief Executive Officer,…

Read More...
AstraZeneca to invest $360m in advanced manufacturing facility in Ireland

Articles